Trials / Recruiting
RecruitingNCT06094426
Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors
A Single-arm Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injections for the Treatment of Advanced Solid Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a multicenter, single-arm, open design designed to evaluate the safety and tolerability of Autologous Tumor Infiltrating Lymphocyte Injection in the treatment of patients with advanced solid tumors, as well as pharmacokinetic profiling and efficacy. The trial consists of two phases: dose-escalation and dose-expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT316 | Autologous Tumor Infiltrating Lymphocyte Injection |
Timeline
- Start date
- 2023-02-26
- Primary completion
- 2026-02-26
- Completion
- 2026-02-26
- First posted
- 2023-10-23
- Last updated
- 2025-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06094426. Inclusion in this directory is not an endorsement.